Health
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/fa8e0006b54004d56aaaf67802e05993"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZkxSXa2eGC44hPugXQ9Glg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fa8e0006b54004d56aaaf67802e05993","width":480,"height":217}},"lazy":false},{"type":"text","content":"First and only immunotherapy plus antibody-drug conjugate regimen, used perioperatively, to significantly extend survival for these patients","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"KEYNOTE-B15 is the sixth study demonstrating overall survival with a KEYTRUDA-based regimen in an earlier-stage cancer","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"Late-breaking results from the Phase 3 KEYNOTE-B15 trial were selected for the official Press Program and will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium","length":217,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., February 27, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will be presented for the first time today during an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA630) and are included in the official ASCO GU Press Program.","length":756,"tagName":"p"},{"type":"text","content":"After a median follow-up of 33.6 months, KEYTRUDA plus Padcev, as perioperative treatment, demonstrated a statistically significant and clinically meaningful improvement in EFS, the trial’s primary endpoint, reducing the risk of EFS events by 47% (HR=0.53 [95% CI, 0.41-0.70]; p<0.0001) versus neoadjuvant chemotherapy and surgery in patients with MIBC who are eligib...